Jefferies downgraded Amicus to Hold from Buy with a price target of $14.50, down from $16. Proxy documents show the company did receive extensive pharma takeover interest beyond BioMarin, the analyst tells investors in a research note. As such, Jefferies does not expect additional takeover bids for Amicus.
